Stock Track | GlaxoSmithKline Soars 6.43% Intraday on Strong Q4 Earnings Beat, Dividend Hike and Upbeat Guidance

Stock Track

Feb 04

Shares of GlaxoSmithKline PLC (GSK) soared 6.43% during intraday trading on Wednesday, following the release of its fourth-quarter financial results that significantly exceeded market expectations.

The pharmaceutical giant reported core earnings per share of £0.26 ($0.36) for Q4 2025, beating the FactSet consensus estimate of £0.24. Quarterly sales reached £8.62 billion, also above the expected £8.47 billion. For the full year 2026, the company issued a positive growth outlook, projecting core EPS to increase 7% to 9% and sales to rise 3% to 5%. Additionally, GSK announced a 12.5% increase in its quarterly dividend to 18 pence per share and forecast a dividend of 70 pence for FY2026, enhancing shareholder returns.

The strong quarterly performance was driven by double-digit growth in GSK's specialty medicines portfolio, particularly in HIV treatments, oncology, and immunology drugs. Analyst firms including Jefferies and Bernstein maintained bullish Buy ratings on the stock, citing solid near-term delivery and compelling long-term growth potential, with the company targeting sales exceeding £40 billion by 2031.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1147979171"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147979171\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147979171?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-04 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147979171","market":"us","top_or_hot":-1,"title":"Stock Track | GlaxoSmithKline Soars 6.43% Intraday on Strong Q4 Earnings Beat, Dividend Hike and Upbeat Guidance","media":"Stock Track","content":"<p>Shares of GlaxoSmithKline PLC (GSK) soared 6.43% during intraday trading on Wednesday, following the release of its fourth-quarter financial results that significantly exceeded market expectations.</p><p>The pharmaceutical giant reported core earnings per share of £0.26 ($0.36) for Q4 2025, beating the FactSet consensus estimate of £0.24. Quarterly sales reached £8.62 billion, also above the expected £8.47 billion. For the full year 2026, the company issued a positive growth outlook, projecting core EPS to increase 7% to 9% and sales to rise 3% to 5%. Additionally, GSK announced a 12.5% increase in its quarterly dividend to 18 pence per share and forecast a dividend of 70 pence for FY2026, enhancing shareholder returns.</p><p>The strong quarterly performance was driven by double-digit growth in GSK's specialty medicines portfolio, particularly in HIV treatments, oncology, and immunology drugs. Analyst firms including Jefferies and Bernstein maintained bullish Buy ratings on the stock, citing solid near-term delivery and compelling long-term growth potential, with the company targeting sales exceeding £40 billion by 2031.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GlaxoSmithKline Soars 6.43% Intraday on Strong Q4 Earnings Beat, Dividend Hike and Upbeat Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GlaxoSmithKline Soars 6.43% Intraday on Strong Q4 Earnings Beat, Dividend Hike and Upbeat Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-04 23:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of GlaxoSmithKline PLC (GSK) soared 6.43% during intraday trading on Wednesday, following the release of its fourth-quarter financial results that significantly exceeded market expectations.</p><p>The pharmaceutical giant reported core earnings per share of £0.26 ($0.36) for Q4 2025, beating the FactSet consensus estimate of £0.24. Quarterly sales reached £8.62 billion, also above the expected £8.47 billion. For the full year 2026, the company issued a positive growth outlook, projecting core EPS to increase 7% to 9% and sales to rise 3% to 5%. Additionally, GSK announced a 12.5% increase in its quarterly dividend to 18 pence per share and forecast a dividend of 70 pence for FY2026, enhancing shareholder returns.</p><p>The strong quarterly performance was driven by double-digit growth in GSK's specialty medicines portfolio, particularly in HIV treatments, oncology, and immunology drugs. Analyst firms including Jefferies and Bernstein maintained bullish Buy ratings on the stock, citing solid near-term delivery and compelling long-term growth potential, with the company targeting sales exceeding £40 billion by 2031.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"","article_id":"1147979171","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147979171","pubTimestamp":1770217248,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of GlaxoSmithKline PLC (GSK) soared 6.43% during intraday trading on Wednesday, following the release of its fourth-quarter financial results that significantly exceeded market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"个股追踪|葛兰素史克盘中飙升6.43%，因第四季度盈利强劲、股息上调和乐观指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1},"content_text":"Shares of GlaxoSmithKline PLC (GSK) soared 6.43% during intraday trading on Wednesday, following the release of its fourth-quarter financial results that significantly exceeded market expectations.The pharmaceutical giant reported core earnings per share of £0.26 ($0.36) for Q4 2025, beating the FactSet consensus estimate of £0.24. Quarterly sales reached £8.62 billion, also above the expected £8.47 billion. For the full year 2026, the company issued a positive growth outlook, projecting core EPS to increase 7% to 9% and sales to rise 3% to 5%. Additionally, GSK announced a 12.5% increase in its quarterly dividend to 18 pence per share and forecast a dividend of 70 pence for FY2026, enhancing shareholder returns.The strong quarterly performance was driven by double-digit growth in GSK's specialty medicines portfolio, particularly in HIV treatments, oncology, and immunology drugs. Analyst firms including Jefferies and Bernstein maintained bullish Buy ratings on the stock, citing solid near-term delivery and compelling long-term growth potential, with the company targeting sales exceeding £40 billion by 2031.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}